Samsung Says Eye Med Biosimilar Won't Flout Regeneron's IP
Samsung Bioepis has argued in a London court that its planned eye medicine biosimilar will not infringe Regeneron's patents over the treatment, doubling down on plans to market its own version....To view the full article, register now.
Already a subscriber? Click here to view full article